Lower Contribution of Factor V Leiden or G200210A mutations to ischemic stroke in patients with clinical risk factors : pair-matched case-control study (CROSBI ID 116306)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Eterović, Davor ; Titlić, Marina ; Čulić, Viktor ; Zadro, Renata ; Primorac, Dragan
engleski
Lower Contribution of Factor V Leiden or G200210A mutations to ischemic stroke in patients with clinical risk factors : pair-matched case-control study
It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls differed from patients in prevalences of clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls less than 65 years old. Each patient had its own control, tightly matched in clinical risk factors. Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated from Miettenan's formula. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3% (P=0.02) and 7.5% (P=0.04) respectively, and 2.5% for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (OR=3.6, 95% CI: 1.4-9.3), especially among women (OR=4.6, 95% CI 1.2-17.8), normotonics (OR=9.2, 95% CI: 1.1-17.8) and those having normal cholesterol (OR=5.9, 95% CI: 1.6-21.2) and triglyceride serum concentrations (OR=4.3, 95% CI: 1.5-12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in healthy controls, but there was an apparent negative interaction of these mutations with clinical risk factors.
factor V Leiden; G20210A; stroke
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
13 (2)
2007.
188-193
objavljeno
1076-0296
10.1177/1076029606298999
Povezanost rada
Temeljne medicinske znanosti, Kliničke medicinske znanosti